O11 Final analysis of a phase I/II study with CV9103: An intradermally administered prostate cancer vaccine based on self-adjuvanted mRNA (RNActive®)
Year: 2012
Type: conference-abstract
Source: European Urology Supplements
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2000751483